释 义 瑞格列奈
例 句 Objective: To observe the clinical efficacy and safety of combined treatment of repaglinide and acarbose in aged patients with diabetes type 2. 目的：观察瑞格列奈、阿卡波糖联合治疗老年性2型糖尿病患者的临床疗效及安全性。
作者： Dong-Gyun Han
Arthritis and diabetes mellitus are highly prevalent diseases with a total of over 350 million patients worldwide. The most common types of arthritis and diabetes mellitus are osteoarthritis (OA) and type 2 diabetes mellitus (T2DM), respectively. OA affects 14% of adults aged ≥25 years, and 34% of these patients are aged >65 years; similarly, T2DM affects 12% of adults aged ≥20 years, and 26% of these are aged >65 years. A recent survey estimated that the prevalence of OA was higher in individuals with T2DM than in those without T2DM. Thus, T2DM is generally recognized as a comorbidity of arthritis, while some previous studies have focused on diabetes as a risk factor of arthritis. Anyway, it is evident that T2DM is closely associated with an increased incidence and prevalence of OA, though the reasons remain unclear.Because T2DM frequently co-exists with OA, there is a possibility of concurrent administration of REP and CEL. Hence, a bioanalytical method of simultaneous determination of REP and CEL could be useful and efficient for further pharmaceutical development and therapeutic optimization. To date, several bioanalytical methods have been developed and validated for quantitative determination of REP or CEL individually using HPLC with UV/Vis detection or using liquid chromatography with tandem mass spectrometry (LC-MS/MS) systems. However, these methods are associated with a few limitations, such as an insufficient sensitivity, relatively large sample volume, and/or time-consuming liquid–liquid extraction procedures with volatile solvents that are potentially hazardous to health. Moreover, LC-MS/MS methods require relatively complex and/or expensive instrumentation, which may not be affordable for small-sized laboratories and companies in resource-limited settings. To the best of our knowledge, there have been no reported methods of simultaneous quantification of REP and CEL in biological samples using HPLC coupled with a fluorescence detector (HPLC-FL). Furthermore, a previous in vitro study reported that CEL inhibited REP metabolism in pooled human liver microsomes (HLM) with a Ki of 3.1 μM. This suggests the possibility of pharmacokinetic drug interaction between REP and CEL, but no information is currently available regarding this issue.